請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/57419
標題: | 聚氰基丙烯酸乙酯藥物載體系統製備之研究 Studies on the Synthesis of Poly(ethyl cyanoacrylate) Nanoparticles as Drug Carrier Systems |
作者: | Yi-Chieh Lee 李怡潔 |
指導教授: | 王勝仕 |
關鍵字: | 阿茲海默症,血腦屏障,Clioquinol,聚氰基丙烯酸乙酯, Alzheimer’s disease,blood brain barrier,Clioquinol,poly ethyl cyanoacrylate, |
出版年 : | 2014 |
學位: | 碩士 |
摘要: | 在台灣已逐漸步入高齡化的社會,台灣失智症協會(Taiwan Alzheimer’s Disease Association)已估計台灣的失智人口到2060年時將逼近80萬人,而失智症中阿茲海默症之病患又佔其多數,如何有效地預防及治療阿茲海默症將會是一個相當重要之課題。
Clioquinol (CQ)為一種金屬螯合劑,已經在文獻中證實可以用以治療阿茲海默症(AD),但由於CQ本身之特性導致其無法順利地通過血腦屏障(Blood brain barrier);研究人員發現若使用奈米顆粒作為藥物載體,可利用其藥物載體之標靶性,可以使藥物通過血腦屏障並發揮其功效。 因已有許多文獻指出聚氰基丙烯酸烷基酯(Poly alkyl cyanoacrylate,PACA)及聚氰基丙烯酸丁酯(Poly butyl cyanoacrylate, PBCA)等具有具有生物相容性(Biocompatibility)及生物可降解性(Biodegradability),可以作為藥物載體幫助藥物順利地送達目的地。此論文中主要是利用聚氰基丙烯酸乙酯(Poly ethyl cyanoacrylate,PECA)作為藥物載體,利用調整其起始條件,得到吾人所需之大小以通過血腦屏障,並測量其性質、藥物釋放速率等,以了解其特性,以便日後實際運用於治療阿茲海默症上。 In Taiwan, we are entering aging society. Taiwan Alzheimer’s Disease Association estimates that the population of dementia in Taiwan will be near to 800000 in 2060. Alzheimer’s disease makes up the greatest number of cases among all causes of dementia. Therefore, how to prevent and cure Alzheimer’s disease effectively is becoming an important issue. Clioquinol is one of the metal chelating agent and has been found to be beneficial in the treatment for Alzheimer's disease. While clioquinol itself cannot easily pass through the blood brain barrier, the research showed that, with nanoparticles used as the drug carriers, the targeting property/feature of the drug carriers would aid in the passage of clioquinol across the blood brain barrier and thus exerting its effects. Many studies have demonstrated that, due to their biocompatibility and biodegradability, poly alkyl cyanoacrylates (PACA), and poly butyl cyanoacrylate (PBCA) can be used as the drug carriers and help the drugs reach the destination. In this thesis, the poly ethyl cyanoacrylate (PECA) was used as a drug carrier system. In order to obtain the proper size of PECA nanoparticle drug carrier to pass the blood brain barrier, several key parameters of the synthesis of PECA nanoparticle drug carriers were examined. The important properties/features along with the drug release rates of the PECA nanoparticle drug carrier were also determined. We believe the outcome from this research may contribute to the treatment for Alzheimer’s disease. |
URI: | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/57419 |
全文授權: | 有償授權 |
顯示於系所單位: | 化學工程學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 1.62 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。